Design principle for the construction of expression constructs for gene therapy

US7074772B2 · kind B2 · utility

Assignee

• Mologen AG · DE

Inventors

• Burghardt Wittig · Berlin, DE
• Claas Junghans · Berlin, DE

Key dates

• Filing date: Aug 27, 2002
• Grant date: Jul 11, 2006
• Expiry date: Jun 1, 2024

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S977/916
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles of peptides.